B-Group-Tech

/B-Group-Tech

About B-Group-Tech

This author has not yet filled in any details.
So far B-Group-Tech has created 2 blog entries.
21 12, 2020

PR Releases & Articles and Case Studies  

2022-12-22T09:11:51+00:00

Case Report Article (Frontiers, Oct 2022)

Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD:
Case report

Cannabidiol (CBD) rich products are successfully used in some countries for treating symptoms associated with autism spectrum disorder (ASD). Yet, CBD provides insufficient intervention in some individuals, or for some characterizing symptoms of ASD, raising the need for improved compositions. The current study presents a case wherein pure CBD was sufficient for treating ASD during childhood and early adolescence. However, it became insufficient during puberty accompanied by increased hyperactivity, agitation, and frequent severe aggressive behavior. Increasing the CBD dose did not result in significant improvement. Enriching the pure CBD with a carefully selected blend of anxiolytic and calming terpenes, resulted in gradual elimination of those aggressive events. Importantly, this was achieved with a significantly reduced CBD dose, being less than one-half the amount used when treating with pure CBD. This case demonstrates a strong improvement in efficacy due to terpene enrichment, where pure CBD was not sufficient. Combined with terpenes’ high safety index and the ease with which they can be incorporated into cannabinoid-containing products, terpene-enriched CBD products may provide a preferred approach for treating ASD and related conditions. The careful selection of terpenes to be added enables maximizing the efficacy and tailoring the composition to particular and changing.

Read more>

Download PDF>

Article (Molecules journal, 2022)

Optimal Treatment with Cannabis Extracts Formulations Is Gained via Knowledge of Their Terpene Content and via Enrichment with Specifically Selected Monoterpenes and Monoterpenoids.

Abstract

Differences between therapeutic effects of medical cannabis inflorescences and those of their extracts are generally attributed to the differences in administration form and in the resultant pharmacokinetics. We hypothesized that difference may further extend to the composition of the actually consumed drug. Cannabinoid and terpene contents were compared between commercial cannabis inflorescences (n = 19) and decarboxylated extracts (n = 12), and between inflorescences and decarboxylated extracts produced from them (n = 10). While cannabinoid content was preserved in the extracts, a significant loss of terpenes was evident, mainly in the more volatile monoterpenes and monoterpenoids (representing a loss of about 90%). This loss changes the total terpene content, the proportion of monoterpenes out of the total terpenes, and the monoterpene/cannabinoid ratio. Terpene deficiency might impair extracts’ pharmacological efficacy and might contribute to the patients’ preference to inflorescences-smoking. This argues against the validity of terms such as “whole plant” and “full spectrum” extracts and creates a misleading assumption that extracts represent the pharmacological profile of the sourced inflorescences. Furthermore, it reduces the diversity in extracts, such as loss of differences between sativa-type and indica-type. Enriching cannabis extracts with selected terpenes may provide a suitable solution, generating a safe, precise, and reproducible drug with tailored cannabinoid and terpene contents. Careful selection of terpenes to be added enables tailor-made extracts, adjusted for various medicinal aims and for different populations.

Read more>

Download PDF>

Article (Oct 2021) 

Vapor Pressure, Vaping, and Corrections to Misconceptions Related to Medical Cannabis’ Active
Pharmaceutical Ingredients’ Physical Properties and Compositions.

Abstract
Medical cannabis products contain dozens of active pharmaceutical ingredients (APIs) derived from the cannabis plant. However, their actual compositions and relative doses significantly change according to the production methods. Product compositions are strongly dependent on processing step conditions and on components’ evaporation during those steps. Review of the documentation presented to caregivers and to patients show erroneous data or misinterpretation of data related to the evaporation, for example, cannabinoids’ boiling points, as well as confusions between terms, such as boiling, vaporization, and evaporation. Clarifying these aspects is
essential for caregivers, for researchers, and for developers of manufacturing processes. Original and literature data were analyzed, comparing composition changes during various processing steps and correlating the extent of change to components’ vapor pressures at the corresponding temperature. Evaporation-related composition changes start at temperatures as low as those of drying and curing and become extensive during decarboxylation.
The relative rate of components’ evaporation is determined by their relative vapor pressure and monoterpenes are lost first. On vaping, terpenes are inhaled before cannabinoids do. Commercial medical cannabis products are deficient in terpenes, mainly monoterpenes, compared with the cannabis plants used to produce them. Terms, such as ‘‘whole plant’’ and ‘‘full spectrum,’’ are misleading since no product actually reflects the original cannabis plant composition. There are important implications for medical cannabis manufacturing and for the ability to make the most out of the terpene API contribution. Medical cannabis products’ composition and product delivery are controlled by the relative vapor pressure of the various APIs. Quantitative data provided in this study can be used for improvement to reach better accuracy, reproducibility, and preferred medical cannabis compositions.

Read more / download PDF>

Press Release (Feb 2021)

Bazelet launches its Terpene enriched oil brand Femmican, dedicated to Women’s health.
Read more>

PR-Release (June 2021)

Bazelet’s terpene formulations to be incorporated in Canadian cannabis products
Our innovations:

Bazelet has invented a unique way of formulating of medical cannabis oils. Bazelet, doesn’t depend on developing new strains in order to form a large variety of better-performing new oils. Instead, Bazelet’s TOP technology generates improved new oils by blending extracts and by controlling their terpene content, particularly by enriching with scientific-based terpenes selection.
Cannabis inflorescence contains 10-20 different terpenes, varying in amount and proportion and determining the characteristic aroma of the various strains. Processing modifies the terpenes content and, most importantly the terpene profile. Terpenes content of oils is, in many cases, less than one half that of inflorescence and the proportion of low-boiling point terpenes in oil is much smaller than that in the inflorescence.
But this is not mainly about aroma. Terpenes play an important medical role, individually (as in aromatherapy) and, more importantly, in modulating the activity of the cannabinoids in the cannabis oil. Generating oils of exactly selected terpenes composition is easy and is achieved by simple industrial processes. Undesired terpenes are removed by evaporation, while desired terpenes are added, typically ones sourced from plants other than cannabis, e.g. lavender and citrus. The terpene content of Bazelet oils is 50-100% greater than those of common cannabis oils and are therefore referred to as terpenes-enriched.
While manufacturing many formulations of exact composition is straightforward, the main challenge is to discover the preferred composition for each indication or symptom. Some players in the cannabis industry try to collect as much of the terpenes lost during processing and add them back to the oil in order to regenerate the terpene profile of the inflorescence. This approach is questionable, keeping in mind the obvious – the terpene profile of each strain is selected by nature to serve the needs of the plant, e.g. protection from plant diseases, rather than to serve human needs.
Bazelet’s scientific arm, has devoted the last four years to finding which terpenes improves the performance of the cannabis oil for each indication or symptom and which ones have a negative effect. Bazelet has found that given terpenes are helpful in particular indications, but impair the effect in others. Analysis of big data from hundreds of thousands of users, careful study of pre-clinical and clinical data and deep dive into mechanisms of action resulted in formulations specifically designed for different indications. Bazelet has filed about a dozen of patent application families to protect its terpenes-enriched formulations.
As a demonstration, Bazelet has a series of oils for night use and another one for day use. Almost everyone in the cannabis area knows of Indica and Sativa strains, believed to be more suitable for night use and for day use, respectively. What is much less known is that the majority of the terpenes responsible for the difference between the Indica nature and the Sativa nature are lost in the oil manufacturing, so that oils produced from Indica plants do not have Indica nature more than those from Sativa plants. Bazelet enriches its oils with the lost terpenes, but not only with those. Further improvement is gained by enriching with selected terpenes, for example enriching Sativa oils with terpenes that increase focus and alertness, making it more suitable for day function.
Bazelet technology has an additional attractive feature. In addition to the production of terpenes-enriched oils, Bazelet is ready to supply patent-protected terpenes blends to be added to extracts produced in other Geographies. Since the terpenes are extracted from sources other than cannabis, there is no limitation on shipment. Additionally, as the total amount of terpene blend to be added is about 1-2% of the final oil, a small barrel of a given blend is sufficient for the manufacturing of large amounts of terpene-enriched oil.

Contact person: Itai Rogel. +972-4-8414393, itai@b-group.co.il

PR-Release (May 2020)

Bazelet launches its Bcann Oil brand, which is first-of-the kind, proprietary, terpene-enriched medical cannabis oils specially designed for medical needs such as women health, pain treatment, improved sleep and special needs of the elderly population
Bazelet, the largest medical company in Israel, has made a breakthrough in medical cannabis products, in launching multiple lines of terpene-enriched cannabis oils, each one of which being specifically designed for one of various indications, symptoms and personal needs. Bazelet terpene-enriched products are optimized for woman health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic), and for improved night sleep etc.

Read more>

Cannabis and Neurology

Bazelet’s scientific paper dealing with medical cannabis treatment in various neurological conditions was published in the Neurology journal, the official journal of the Israel Neurological association.

 (link to article in Hebrew>)

Download in Hebrew>

Bazelet’s new international patent application

Bazelet’s new international patent application (WO2018015886)
CANNABIS PRODUCTS AND INDUSTRIAL METHODS FOR PRODUCTION THEREOF

Is available online>.

Abstract: Cannabis products and industrial methods for production thereof. A homogeneous composition comprising cannabinoid-containing comminuted cannabis plant material, where at least 70% weight of the comminuted cannabis plant material is of a size greater than 0.3 millimeter and less than 4.2 millimeters; the composition comprises at least 1% by weight moisture and less than 20% by weight moisture; and the cannabinoid concentration in a 1 gram fraction of at least 10 gram sample of said homogeneous composition, is within 15% of the cannabinoid concentration in a separate 1 gram fraction of said 10 gram sample

Bazelet’s new international patent application

Bazelet’s new international patent application (WO2017182950) CANNABIS-ENRICHED ENZYMATICALLY TREATED THERAPEUTIC COMPOSITION 
is available online>.

Abstract: A cannabis-enriched enzymatically treated therapeutic composition. A therapeutic composition is described including water, glucose, glucose reaction product other than sucrose and fructose; a selected amount of a cannabinoid, a cannabinoid reaction product; optionally a terpene and optionally a terpene reaction product. Methods of making and using the compositions are also described.

PR Releases & Articles and Case Studies   2022-12-22T09:11:51+00:00